Poolbeg Pharma PLC (AIM:POLB)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 52.68M +122.2% |
| Revenue (ttm) | n/a |
| Net Income | -5.46M |
| EPS | -0.01 |
| Shares Out | 763.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,845,626 |
| Open | 7.21 |
| Previous Close | 7.20 |
| Day's Range | 6.80 - 7.21 |
| 52-Week Range | 3.30 - 9.30 |
| Beta | 1.84 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 18, 2026 |
About Poolbeg Pharma
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated ... [Read more]
Financial Performance
Financial StatementsNews
Poolbeg Pharma Quarterly report: H1 2026
Poolbeg Pharma has published its H1 2026 quarterly earnings report on September 29, 2026.
Poolbeg Pharma Slides: H1 2026
Poolbeg Pharma has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 29, 2026.
Poolbeg Pharma Transcript: Study update
POLB 001's interim TOPICAL trial results show strong safety in multiple myeloma patients, with the Safety Review Committee endorsing continued study and no protocol changes. The program is attracting significant commercial and partnering interest, supported by robust payer research and a clear regulatory path.
Poolbeg Pharma Press release: Study update
Poolbeg Pharma issued a press release on September 24, 2026, disclosing material business information to investors.
Poolbeg Pharma Slides: Study update
Poolbeg Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
Poolbeg Pharma hails positive interim data from cancer-related trial in UK
Poolbeg Pharma Slides: Company presentation
Poolbeg Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Poolbeg Pharma Slides: Corporate presentation
Poolbeg Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Poolbeg Pharma Earnings Call Transcript: H2 2025
POLB 001 is advancing toward a key clinical data readout in CRS prevention, supported by strong financials, strategic partnerships, and a robust patent portfolio. The company is also preparing to launch an oral GLP-1 trial for obesity, targeting large and growing markets.
Poolbeg Pharma Annual report: H2 2025
Poolbeg Pharma has published its H2 2025 annual report on April 28, 2026.
Poolbeg Pharma Slides: H2 2025
Poolbeg Pharma has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 28, 2026.
Poolbeg Pharma Annual report: H2 2025
Poolbeg Pharma has published its H2 2025 annual report on April 28, 2026.
Poolbeg Pharma Transcript: Study Update
POLB 001 is advancing to a phase IIa trial as a first-in-class oral prophylactic for cancer immunotherapy-induced CRS, with strong preclinical and phase 1 data, FDA orphan drug status, and rapid proof-of-concept data expected in 2024. The program targets a multibillion-dollar market and aims to expand immunotherapy access.
Poolbeg Pharma Press release: Study Update
Poolbeg Pharma issued a press release on September 29, 2025, disclosing material business information to investors.
Poolbeg Pharma Quarterly report: H1 2025
Poolbeg Pharma has published its H1 2025 quarterly earnings report on September 29, 2025.
Poolbeg Pharma Slides: Company Presentation
Poolbeg Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2025.
Poolbeg Pharma Transcript: Investor Update
POLB001 has received FDA orphan drug designation, unlocking regulatory incentives and exclusivity. A phase 2A trial in multiple myeloma patients will start in H2 2025, with interim data in H1 2026. The program targets a $10B+ market, with strong pharma interest and a robust cash runway.
Poolbeg Pharma Slides: Investor Update
Poolbeg Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2025.
Poolbeg Pharma Annual report: H2 2024
Poolbeg Pharma has published its H2 2024 annual report on May 20, 2025.
Poolbeg Pharma Annual report: H2 2024
Poolbeg Pharma has published its H2 2024 annual report on May 20, 2025.
Poolbeg Pharma Slides: Company Presentation
Poolbeg Pharma has posted slides in relation to its latest quarterly earnings report, which was published on January 1, 2025.
Poolbeg Pharma Quarterly report: H1 2024
Poolbeg Pharma has published its H1 2024 quarterly earnings report on September 18, 2024.
Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovativ...
Poolbeg Pharma PLC Announces Notification of Major Holdings
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microso...
Poolbeg Pharma PLC Announces Change of Registered Address
Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and ...